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A B S T R A C T
Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target 
hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL 
during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if 
there was a clinical impact of this statement in the anemia management of chronic kidney 
disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain.
Methods: This was an observational and cross-sectional study carried out in CKD patients 
not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous 
ESA to another ESAs (converted) since January 2011.
Results: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study 
visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 
11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients 
maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve 
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cardiovascular complications. In this regard, contrary to ini-
tial observational studies that suggested positive outcomes 
associated with higher achieved Hb levels,5,6 subsequent large 
multicentre randomized controlled trials (RCTs) and related 
meta-analyses7-10 have demonstrated an association between 
allocation to higher Hb levels (which is also associated with 
higher ESA doses) and an increased risk of cardiovascular 
complications without a benefit on mortality.
Treatment of anemia with ESAs in CKD patients has thus 
experienced a significant shift from using Hb levels as a 
surrogate end-point, to a more individualized ESA therapy 
that takes into consideration Hb targets, required ESA doses, 
and patients’ comorbidities, as well as a recent recommen-
dation of administering the lowest possible ESA dose requi-
Introduction
Anemia is a common complication of chronic kidney disease 
(CKD), that is associated with a reduced quality of life (QoL)1 
and is a risk factor for morbidity and mortality. Thus, erythro-
poiesis-stimulating agents (ESAs) are considered as a key 
therapy in the management of CKD-related anemia,2-4 consi-
derably reducing the need of blood transfusions and impro-
ving the QoL of these patients, among other beneficial effects.
The use of ESAs aiming to normalize hemoglobin (Hb) 
levels (≥13 g/dL), as opposed to the partial correction of ane-
mia (9.0-11.0 g/dL) has been associated with minor improve-
ments in QoL (mainly fatigue),3 but with an increased risk of 
patients and 7.9% of those converted had Hb levels >13 g/dL. Hb levels were similar across 
subgroups of patients, regardless of the presence of significant comorbidities.
Conclusions: Anemia management in CKD patients treated with ESAs by Spanish nephrologists 
seems to be aimed at preventing Hb levels <11 g/dL, while <50% of patients were within the 
narrow recommended Hb target range. This, together with the lack of individualization in Hb 
targets according to patients’ comorbidities show that there is still room for improvement 
in renal anemia management in the clinical setting.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Impacto clínico de las recomendaciones de 2010 del grupo de trabajo 
ERBP sobre el tratamiento de la anemia en la enfermedad renal crónica 
sin diálisis: estudio ACERCA
R E S U M E N
Introducción y objetivo: El grupo de trabajo europeo en anemia-ERBP recomendó en 2010 
mantener los niveles de Hb entre 11-12 g/dL sin exceder intencionadamente de 13 g/dL 
durante el tratamiento con agentes estimuladores de la eritropoyesis (AEE). Este estudio 
evaluó si se produjo un impacto clínico de esta declaración en el tratamiento de la anemia 
en la enfermedad renal crónica (ERC) con AEE en la práctica clínica.
Metodología: Estudio transversal, observacional y multicéntrico en pacientes con anemia 
secundaria a ERC y no sometidos a diálisis, que iniciaron tratamiento de la anemia (nuevos) 
o pasaron de unos AEE a otros (transición de AEE) a partir de enero de 2011.
Resultados: De los 441 pacientes evaluados, el 67,6% eran nuevos y el 32,4% estaban en 
situación de transición. En la visita de estudio, el 42,5% de los pacientes nuevos habían 
alcanzado el rango de Hb de 11-12 g/dL (niveles medios de 11,3 ± 1,3 g/dL frente a 10,1 ± 
0,9 g/dL al inicio del tratamiento con AEE), y el 35,3% de pacientes en situación de transición 
mantuvieron los niveles de Hb dentro del rango recomendado. A pesar de ello, el 8,2% de 
los pacientes nuevos y el 7,9% de aquellos en situación de transición tenían niveles de Hb 
> 13 g/dL. Los niveles de Hb fueron similares, independientemente de la presencia o no de 
comorbilidades significativas.
Conclusiones: En las Unidades de Nefrología de España, el manejo de la anemia en pacientes 
con ERC no en diálisis en tratamiento con AEE parece dirigido a evitar niveles de Hb < 11 g/dL, 
aunque menos del 50% de los pacientes se encuentran dentro del estrecho rango recomendado. 
Ello, junto a la falta de individualización del objetivo de Hb en función de la presencia de 
comorbilidades, muestra que aún queda margen de mejora en el tratamiento de la anemia 
en la ERC con AEE en la práctica clínica.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0).
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Information about the medical history and patients’ cha-
racteristics were collected from patients’ medical charts at 
the study visit. Hb levels, transferrin saturation index (TSAT) 
and ferritin levels were recorded, as well as other biochemical 
parameters (serum creatinine, C reactive protein (CRP), albu-
min and iron). Characteristics of ESA therapy, iron supple-
mentation (route of administration, dose and dosing 
schedule), and data regarding adverse events, transfusions 
and the concomitant use of other medications were also 
collected. Estimated glomerular filtration rate (eGFR) was cal-
culated according to the MDRD formula.15
At the study visit the distribution of ESA in naïve patients 
was: epoetin alfa (n=5, 1.7%), epoetin beta (n=5, 1.7%), darbe-
poetin alfa (n=38, 13.1%) and continuous erythropoietin recep-
tor activator (C.E.R.A.) (n=242, 83.4%). Among patients that 
were treated previously with an ESA and shifted to another 
(converted patients) the distribution was: epoetin alfa (n=3, 
2.1%), epoetin beta (n=6, 4.2%), darbepoetin alfa (n=28, 19.6%) 
and C.E.R.A. (n=106, 74.1%).
Statistical analysis
As the primary endpoint was the percentage of patients that, 
at the study visit, maintained Hb levels within the target 
range of 11-12 g/dL (as recommended by the Anemia Working 
Group of the ERBP in 2010), the sample size was estimated 
assuming a standard deviation (SD) of Hb values of 0.5 g/dL, 
in the range of SD reported in previous studies for patients 
achieving mean Hb levels within the target range. With a pre-
cision of 0.04 and a type I error rate of 0.05, we calculated that 
632 patients would be required, allowing for a percentage of 
non-evaluable patients not exceeding 5%.
Data were summarized using descriptive statistics. Continuous 
variables were described using mean, median, standard devia-
tion, and minimum and maximum values and were compared 
using a t-test or a non-parametric method (Mann-Whitney U 
test or Wilcoxon test), as appropriate. Absolute frequencies and 
valid percentages were calculated and compared using chi-
squared test or Fisher’s exact test, as appropriate. The Charlson 
comorbidity index (CCI) was calculated in all patients, and a 
Spearman’s correlation was performed to assess the association 
of CCI with Hb levels, and ESA resistance index (ERI).
In addition to the previously described variables, compa-
risons between mean Hb levels achieved by subgroups of 
patients according to their comorbidities were performed: 
diabetes vs no diabetes, cardiovascular disease vs no cardio-
vascular disease, cerebrovascular disease vs no cerebrovas-
cular disease, cancer vs no cancer.
Since a significant proportion of patients converted from 
an ESA to another where shifted from shorter-acting ESA to 
C.E.R.A. (Mircera®; F. Hoffmann-La Roche Ltd, Basel, 
Switzerland) in our study, and the scarce data available about 
this conversion in the clinical setting, especially among CKD 
patients not on dialyisis, dose conversion factors between the 
previous ESA and C.E.R.A. were estimated using a lineal 
regression model (without a constant value), with the dose of 
the prior ESA as the dependent variable and the dose 
of C.E.R.A. as the independent variable.
red to achieve the target Hb levels.11,12 After the publication 
of the Trial to Reduce Cardiovascular Events with Aranesp® 
Therapy (TREAT study),8 the Anemia Working Group of the 
European Renal Best Practice (ERBP) recommended to main-
tain Hb levels between 11-12 g/dL, without intentionally 
exceeding 13 g/dL.13 In this statement, caution was advised 
when considering Hb targets in diabetic patients, especially 
those with cardiovascular disease, and in patients with 
cancer; as well as to consider the dose of ESA required. The 
Anemia Group of the Spanish Society of Nephrology (S.E.N.) 
pointed out that ultimately Hb targets should be individua-
lized, taking into account patients’ comorbidities, maximum 
doses of ESAs and Hb correction speed, as factors to redefine 
Hb targets.14 Finally, a recent position statement of the ERBP 
on the management of CKD-related anemia in Europe 12 
called for special caution for patients with specific risk fac-
tors such as diabetes, cerebrovascular disease or cancer, in 
which it is advised to target to lower Hb levels (10 g/dL) during 
ESA therapy.
In view of the current statements on anemia management 
in CKD patients treated with ESA, it is of paramount relevance 
to analyze the impact of the experts’ recommendations in 
routine clinical practice. The main objective of our study was 
to evaluate whether there has been a change in the perception 
and attitude of nephrologists in the anemia management with 
ESAs in anemic CKD patients not on dialysis since the recom-
mendations of the Anemia Working Group of ERBP in 2010 
were issued.13
Material and methods
Study design
This was an observational, cross-sectional, multicentre study 
carried out in nephrology units of 30 Spanish hospitals. The 
participating centers voluntarily agreed to participate in the 
study and no previous selection was made. The study was 
conducted in accordance with the Guidelines for Ethical 
Review of Epidemiological Studies, Spanish Society of 
Epidemiology, the principles of the Declaration of Helsinki 
and its subsequent amendments. The protocol was approved 
by the Ethics Committee of the Hospital Clinic (Barcelona, 
Spain), and all patients gave their written informed consent 
to participate in the study.
Patient population and study procedures
Inclusion criteria were patients older than 18 years with ane-
mia secondary to CKD not on dialysis, who started ESA 
treatment for anemia (naïve patients), or patients who were 
under ESA treatment previously and were shifted to another 
ESA according to the investigator criterion (converted 
patients) after six months since the last recommendations of 
the Anemia Working Group of ERBP were issued 13 (January 
2011). Patients who were in an ESA dose adjustment period 
or patients who had a functioning kidney transplant were 
excluded.
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Overall, the mean age was 73.1±13.0 years, and 229 patients 
(51.9%) were women. Nearly 80% of patients were in CKD sta-
ges 3-4, and vascular disease (n=130, 29.7%) and diabetes 
(n=113, 25.8%) were the predominant etiologies. As for conco-
mitant diseases, both diabetes and cardiovascular disease 
were reported in nearly 50% of patients. In addition, the mean 
Charlson comorbidity index revealed a relatively high morbi-
dity in our population (3.6±1.6) (Table 1).
Except for a minor difference in the mean body mass index 
(27.9±4.9 kg/m2 in naïve vs 26.7±4.9 kg/m2 in converted 
patients; p<0.05), baseline characteristics were not signifi-
cantly different between both groups, with similar percenta-
ges of patients with diabetes, cerebrovascular disease, 
cardiovascular disease and cancer (Table 1).
There was a negative correlation between CCI and Hb levels 
(r=–0.185, p<0.001) when the overall population was evaluated. 
Similar results were obtained for naïve patients (r=–0.234, 
p<0.001), but not for converted patients. No significant asso-
ciation was found between the CCI and ERI either in the whole 
population (r=–0.003; p=0.949), or in patients’ subgroups [(naïve 
patients: r=–0.004; p=0.957; converted patients: (r=0.053; p=0.580)].
Treatment of anemia
At correction/conversion onset, 242 (83.4%) naïve patients and 
106 (74.1%) of those converted from other ESAs had started 
C.E.R.A., and the main reason for ESA change in converted 
patients was less frequent administration of treatment in 
51.1% of cases, according to the study investigators. Other 
ESAs prescribed were: darbepoetin alfa (n=38, 13.1% and n=28, 
A level of 0.05 was considered to be statistically significant 
for all analyses. Statistical analyses were performed with the 
Statistical Package for the Social Sciences (SPSS) version 17.0 
(SPSS Inc., Chicago, IL, USA).
Results
Patients and baseline characteristics
A total of 455 patients were enrolled in the study, of which 
14 patients were excluded from the analyses due to the 
following reasons: lack of informed consent form (n=1); not 
meeting inclusion criteria (n=1); different ESAs at the start 
and at study visit (n=3); not naïve or converted from a previous 
ESA, and/or lack of information on either Hb, etiology or stage 
of CKD, or age (n=9). Thus, the evaluable population included 
441 patients, of which 298 (67.6%) were naïve and 143 (32.4%) 
had been converted from other ESAs.
Table 1 – Baseline characteristics of participating 
patients
Characteristics Naïve 
patients
Converted 
patients
Total
N=298 N=143 N=441
Age (years), mean±SD 72.9±12.5 73.5±3.9 73.1±13.0
Female, n (%) 152 (51.0) 77 (53.8) 229 (51.9)
Caucasian, n (%) 295 (99.0) 141 (98.6) 436 (98.9)
BMI (kg/m2), mean±SD 27.9±4.9 26.7±4.9 27.5±4.9
eGFR (mL/min/1.73m2), 
mean±SD 
25.1±10.3 25.3±9.8 25.2±10.1
CKD stage, n (%)
2 7 (2.4) 1 (0.7) 8 (1.9)
3 92 (31.4) 38 (27.3) 130 (30.1)
4 142 (48.5) 76 (54.7) 218 (50.5)
5 52 (17.7) 24 (17.3) 76 (17.6)
CKD etiology, n (%)
Vascular 93 (31.3) 37 (26.2) 130 (29.7)
Diabetic 70 (23.6) 43 (30.5) 113 (25.8)
Glomerular 30 (10.1) 17 (12.1) 47 (10.7)
Other/unknown 104 (35.0) 44 (31.2) 148 (33.5)
Previous ESAs, n (%)a
Darbepoetin - 65 (59.1) 65 (59.1)
Epoetin alfa - 17 (15.5) 17 (15.5)
Epoetin beta - 28 (25.5) 28 (25.5)
Concomitant diseases, n (%)
Diabetes 135 (45.3) 64 (44.8) 199 (45.9)
Cerebrovascular disease 33 (11.3) 18 (12.6) 51 (11.8)
Cardiovascular disease 147 (49.3) 67 (46.9) 214 (48.5)
Cancer 41 (13.8) 14 (9.8) 55 (12.5)
Charlson’s Comorbidity 
Indexb, mean±SD
3.7±1.6 3.4±1.5 3.6±1.6
Hb (g/dL), mean±SD 11.3±1.3 11.5±1.3 11.4±1.3
Ferritin (ng/mL), mean±SD 255.2±226.6 260.2±239.8 256.8±230.6
TSAT (%), mean±SD 25.7±13.2 25.4±12.4 25.6±13.0
Serum iron (μg/dL), 
mean±SD
69.5±28.5 65.3±30.9 68.2±29.2
a p value not significant  
b p < 0.05 (naïve vs converted patients)
Table 2 – Overall description of anemia treatments used
Naïve patients (n=298) Correction/
conversion onset
Study visit
ESA dose, n (mean±SD)a
C.E.R.A. (μg/month)b 234 (62.9±26.0) 220 (59.5±25.9)
Darbepoetin (μg/week)  38 (25.4±15.8)  40 (23.1±16.8)
Epoetin alfa (IU/week) 5 (4800.0±3033.2) 5 (4200.0±447.2)
Epoetin beta (IU/week) 5 (4800.0±1303.8) 5 (4800.0±1303.8)
Iron supplementation, n (%)c 167 (89.8) 175 (87.5)
Oral 125 (74.9) 146 (83.4)
IV 42 (25.1) 29 (16.6)
Converted patients (n=143)
ESA dose, n (mean±SD)a 
C.E.R.A. (μg/month) 105 (74.8±36.7) 102 (80.6±42.7)
Darbepoetin (μg/week) 28 (23.3 ±10.6) 28 (23.8±12.0)
Epoetin alfa (IU/week) 3 (13333.3±5773.5) 3 (10000.0±0.0)
Epoetin beta (IU/week) 6 (6833.3±2562.6) 8 (4906.3±2298.8)
Iron supplementation, n (%)c 67 (84.8) 68 (85.0)
Oral 59 (88.1) 57 (83.3)
IV 8 (11.9) 11 (16.2)
a not significant  
b p< 0.05
c p < 0.01
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Details about C.E.R.A. starting doses in naïve and converted 
patients are summarized in Table 3.
Target hemoglobin levels
Analysis of the change in Hb levels between correction/con-
version onset and the study visit showed that mean Hb levels 
increased significantly in naïve patients from 10.1±0.9 g/dL to 
11.3±1.3 g/dL (p<0.001), as expected. For converted patients, 
after the switch from another ESA, mean Hb levels remained 
stable (11.4±1.2 g/dL vs 11.5±1.3 g/dL at the study visit).
As shown in Figure 1, 12.9% of naïve patients started ESA 
with Hb levels >11 g/dL. When Hb levels were analyzed by 
ranges (<11 g/dL, 11-12 g/dL, >12 g/dL), the percentage of naïve 
patients who achieved Hb levels in the target range of 11-12 g/
dL increased from 10.8% (n=32) at the start of the correction 
period to 42.5% (n=125) at the study visit. In converted 
patients, a similar percentage of patients maintained Hb 
within the target range after switching from another ESA 
[39.4% (n=56) vs 35.3% (n=49)] (Fig. 1). Nonetheless, at study 
visit 24.2% of naïve patients and 37.4% of those converted had 
Hb levels >12 g/dL. Moreover, at correction/conversion onset 
19.6%, for naïve and converted patients, respectively), epoetin 
alfa (n=5, 1.7% and n=3, 2.1%, respectively) and epoetin beta 
(n=5, 1.7% and n=6, 4.2%, respectively).
Regarding iron supplementation, 167 (89.8%) of naive 
patients and 67 (84.8%) of converted patients received iron 
supplementation, mainly orally in 74.9% and 88.1% of patients, 
respectively (Table 2).
At the study visit, after a mean of 6.8±3.1 months from the 
correction/conversion onset, 243 (82.9%) naïve patients and 
103 (72.5%) patients on the maintenance phase remained on 
C.E.R.A. treatment. An overview of the ESA dose and iron 
therapy is provided in Table 2.
For naïve patients who started treatment with C.E.R.A., the 
initial mean weight adjusted dose was 1.0±0.4 μg/kg/month, 
which was significantly lower than the dose recommended 
in the Summary of Product Characteristics (SPC) of 1.2 μg/kg/
month (p<0.001). In patients converted from other ESAs to 
C.E.R.A., the estimated dose conversion factor increased as 
the dose ranges of previous ESA were higher. In these patients, 
mean starting doses were lower than the recommended ini-
tial dose by SPC, based on the total weekly epoetin or darbe-
poetin alfa dose at the time of conversion. At the time of the 
study visit, C.E.R.A. doses were similar to the starting doses. 
Table 3 – C.E.R.A. initial dose at correction/conversion onset
Naïve patients
C.E.R.A. C.E.R.A. dose at correction p-value vs SPC
SPC recommended initial dose (μg/kg/month) Mean±SD, (N)
1.2 1.0±0.4, (145) <0.001
Converted patients
Previous weekly epoetin or 
darbepoetin alfa dose ranges
C.E.R.A. C.E.R.A. dose at conversion 
(mean±SD) N
Conversion factor (95% CI) p-value vs SPC
SPC recommended initial 
dose (μg/month)
<4000 120 58.3±22.6, 44 36.0 (32.1-39.9) <0.001
4000-8000 120 84.6±32.9, 38 53.2 (46.4-60.0) <0.001
8000-16000 200  101.9±42.6, 13 73.5 (49.2-97.8) <0.001
>16000 360 94.4±58.5, 3 166.6 (0-395.9) <0.001
0
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Figure 1 – Percentage of naïve and converted patients who achieved the Hb target range of 11-12 g/dL, at correction/
conversion onset and at the study visit.
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vascular disease (95%CI; 10.6-11.4) vs non cerebrovascular 
disease (95% CI; 10.8-11.2)] or cancer [95% CI; 10.6-11.3) vs non 
cancer (95% CI; 10.8-11.1)]. No significant differences in Hb 
levels based on presence/absence of these comorbidities were 
observed in converted patients at any of the study times. 
Specifically, at the study visit the 95% confidence intervals (CI) 
for the mean of Hb levels shown in Figure 2 were as follows: 
[diabetes (10.7-11.3) vs non diabetes (10.8-11.2)]; cardiovascular 
disease (10.7-11.3) vs non cardiovascular disease (10.8-11.2); 
cerebrovascular disease (10.4-11.5) vs non cerebrovascular 
disease (10.8-11.2); cancer (10.4-11.6) vs non cancer (10.8-11.2)]. 
Among diabetic CKD patients with previous cerebrovascular 
disease, 47.6% were within the range of 11-12 g/dL and 38.1% 
had Hb levels >12 g/dL at the study visit.
Iron status
Mean ferritin and TSAT levels were above the lower recom-
mended levels according to the guidelines. None of the iron-
the percentage of patients with Hb levels >13 g/dL was 0.7% 
(n=2) for naïve and 7.0% (n=10) for converted. At study visit, 
these percentages increased, particularly in naïve patients, 
to 8.2% (n=24) and 7.9% (n=11), respectively.
Analysis of Hb levels by patients’ subpopulations according 
to significant comorbidities
An evaluation of mean Hb levels according to the presence or 
absence of several co-morbidities revealed that naïve patients 
with diabetes had lower mean Hb levels than naïve 
patients without diabetes at both correction onset (10.0±1.0 g/
dL vs 10.2±0.8 g/dL, p<0.005) and at the study visit (11.1±1.3 g/dL 
vs 11.5±1.2 g/dL, p<0.01). Likewise, naïve patients with cardio-
vascular disease had lower mean Hb levels than patients 
without cardiovascular disease at the study visit (11.1±1.2 g/
dL vs 11.5±1.3 g/dL, p<0.01) (Figure 2), but no differences were 
observed in achieved Hb levels, as reflected by the mean and 
95% confidence interval (CI), in naïve patients with cerebro-
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Figure 2 – Mean Hb levels at the study visit in naïve and converted patients depending on the presence or absence  
of significant comorbidities.
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merely one in two patients had an Hb level within this recom-
mended Hb target.19
Around one third of patients, both naïve and converted, 
had Hb levels below 11 g/dL at the study visit despite being 
stable on ESA therapy. On the other hand, among naïve 
patients, 12.8% started ESA treatment with Hb levels above 
11 g/dL, while around one forth of patients had Hb levels 
>12 g/dL, and a small but significant proportion of the ove-
rall population (n=35, 8.1%) had Hb >13 g/dL at the study 
visit. These results call for the need to improve anemia 
management both increasing the percentage of patients 
within the target range and avoiding high Hb levels and the 
potential risks associated. The impact of targeting for hig-
her Hb levels, particularly among CKD patients not on 
dialysis, has been recently evaluated in a systematic review 
of 24 RCTs including over 10,000 patients.20 CKD patients 
treated with ESAs allocated to the high Hb group (13 g/dL) 
had an increased risk of hypertension, hospitalization and 
stroke, as compared with patients allocated to the low Hb 
target (10 g/dL). In addition, a significantly higher risk of 
mortality (RR 1.18; 95% CI 1.02-1.37) was also observed in 
the high Hb group. Although the decision of when to start 
ESA therapy and Hb targets during this treatment in CKD 
patients remain controversial issues and are continuously 
revised,12,21 the results of randomized controlled trials and 
the position statement of the ERBP of 2010 at the time of 
the study provided enough information for nephrologists 
to reevaluate, and change accordingly, practice patterns in 
anemia management in these patients. In this regard, our 
results indicate that ESA treatment in the clinical setting 
in Spanish nephrology units seems to be mainly aimed at 
preventing Hb levels to fall below 11 g/dL.
The ACERCA study also evaluated whether Hb targets 
under ESA therapy in CKD patients were individualized, con-
sidering the presence of some frequent comorbidities, such 
as diabetes, cardiovascular or cerebrovascular disease, or 
cancer, as prompted by the ERBP statement. It was thus sur-
prising that in our study, mean Hb levels were similar (or with 
clinically minimal differences) in CKD patients not on dialy-
sis, independent of the presence or absence of significant co-
morbidities, suggesting that there might still be some 
reluctance to individualize Hb targets in patients with signi-
f icant co-morbidities in the clinical practice setting. 
Otherwise, we cannot rule out that our study did not capture 
a delayed or a slow but progressive evolution in the perception 
and attitude of nephrologists towards anemia management, 
since the study was performed only 6 months after the appea-
rance of the position statement of the ERBP of 2010 and before 
the publication of the KDIGO recommendations.21
Another relevant result of our study was the finding that 
in naïve patients, target Hb levels were achieved requiring a 
monthly dose of C.E.R.A. (1.0 μg/kg), which is lower than the 
recommended in the Summary of Product Characteristics 
(SPC) (1.2 μg/kg). Similarly, in patients converted from other 
ESA, the switch to C.E.R.A. required lower doses than those 
recommended in the SPC to maintain Hb levels. Indeed, our 
data suggest that the C.E.R.A. doses required to achieve or 
maintain target Hb levels in CKD patients not on dialysis in 
Spain in clinical practice are relatively low, which is in agre-
related parameters studied varied from correction/conversion 
onset until the study visit, and they were maintained within 
the recommended target ranges for both patients’ groups in 
both periods (Table 4).
Safety
During the study, a total of 8 adverse events (AEs) were repor-
ted in 2 naïve (0.7%) and 4 converted patients (2.8%). None of 
the reported adverse events required specific actions and in 
all cases patients recovered from the event. Two of the AEs 
were classified as serious: a hypercalcemic episode experien-
ced by a converted patient, and a case of acute pulmonary 
edema-congestive heart failure secondary to hypertension, 
reported in a naïve patient 6 days after beginning treatment 
with C.E.R.A. This was the only AE considered by the inves-
tigators to be related to the study medication. During the 
correction period, a total of 6 (2.1%) naïve patients required 
blood transfusions.
Discussion
The results of the ACERCA study provide an overview of the 
clinical practice management of anemia with ESA in CKD 
patients not on dialysis in Spain following the recommen-
dations of the Anemia Working Group of the ERBP in 2010. 
In recent years, anemia guidelines have been changing 
according to the new evidences from the results of rando-
mized controlled trials, Accordingly, Hb targets during ESA 
therapy have been moving towards more conservative goals 
and to its individualization, according to the patients’ cha-
racteristics.
Our results show that less than 50% of naïve or converted 
patients maintained Hb levels within the range of 11-12 g/dL 
and reflect the difficulties associated with achieving and 
maintaining such a narrow target range in routine clinical 
practice also in CKD patients not on dialysis.16-18 This aspect 
has also been confirmed in a recent study which evaluated 
the percentage of patients who achieved the 2007 European 
Medicine Agency (EMA) target range (10-12 g/dL), showing that 
Table 4 – Levels of iron-related parameters  
by subgroups of patients
Correction/
conversion onset
Study visit p-valuea
Naïve patients
Ferritin, ng/mL 261.4±386.8 258.5±231.2 0.367
TSAT, % 25.4±12.3 25.6±12.6 0.896
Serum iron, μg/dL 67.4±30.2 69.7±28.4 0.110
Converted patients 
Ferritin, ng/mL 265.2±223.4 261.2±231.8 0.402
TSAT, % 25.7±11.6 25.8±12.5 0.672
Serum iron, μg/dL 65.7±28.4 64.9±30.6 0.637
a significance for p < 0,05
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on dialysis at the time of the study in Nephrology Units in 
Spain was similar 
In conclusion, the results of the ACERCA study indicate 
that anemia management in Spanish nephrology units is 
mainly aimed at preventing Hb levels below 11 g/dL in the 
clinical setting. The fact that less than 50% of patients had Hb 
levels within the recommended target range of 11-12 g/dL, 
confirms the difficulty to achieve and maintain such a narrow 
target range also in non-dialysis CKD patients treated with 
ESA, as recommended by clinical practice guidelines in the 
real setting, as well as the reluctance to individualize Hb tar-
gets according to patients’ comorbidities. In any case, our 
study shows that there is still room for improving anemia 
management in ESA-treated CKD patients not on dialysis, 
particularly regarding patients with a higher risk to develop 
ESA-related complications.
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ement with two recent cost-minimization analyses conducted 
in Spanish hospitals22,23 where C.E.R.A. doses required to 
achieve target Hb levels in non-dialysis CKD patients were 
also found to be lower than those recommended by the SPC. 
Relatively low doses of C.E.R.A. were also required in non-
dialysis CKD patients shifted from darbepoetin alfa in an 
Italian study,24 and similar results of a beneficial dose con-
version for C.E.R.A. has been also found in the MICENAS II 
study in CKD patients nor on dialysis in Spain.25 These fin-
dings of a dose-saving effect observed with the use of long-
acting ESA, such as C.E.R.A., may have not only economic, 
but also clinical implications.2,22 In this regard, it must be 
emphasized that current guidelines indicate that the patient 
should be prescribed the lowest possible ESA dose to achieve 
the target Hb.11,26 This is especially relevant in ESA-resistant 
patients since a recent consensus pointed out that poorly ESA-
responsive patients is one of the main challenges in anemia 
management in CKD.27 These patients, who usually receive 
higher ESA doses, have a poorer prognosis.11,17,28 Thus, the 
use of long-acting ESA agents, such as C.E.R.A., is an attractive 
alternative that may improve safety and cost-effectiveness 
in this specific subset of patients.
Mean ferritin and TSAT levels were above the minimum 
targets set by guidelines. In our study, 89.8% of naïve patients 
and 84.8% of converted patients received iron supplementa-
tion. In most patients the oral, as opposed to the intravenous 
route, was by far the preferred route of iron administration, 
despite that some studies have shown a higher efficacy of 
intravenous iron as compared to oral iron in these 
patients,29-31 the well-established poor gastrointestinal tole-
rance to oral iron, as well as the reduced intestinal iron 
absorption in CKD patients,32 that could constrain the efficacy 
of oral iron supplements and limit the repletion of iron stores. 
On the other hand, the lack of studies evaluating the long-
term safety of intravenous iron, the need to preserve the 
venous tree for a future vascular accesses, the risk of enhan-
ced oxidative stress, the potential risks of accelerated athe-
rosclerosis, or risk of infections associated with IV iron, 
together with the need to be administered in the hospital 
setting, may be barriers to a more liberal use of intravenous 
iron. The achievement of target levels of ferritin and TSAT 
might have contributed to the relatively low ESA doses requi-
red in our study by allowing an optimization of erythropoie-
sis, since patients with low TSAT and ferritin levels require 
higher ESA doses to achieve target Hb levels.22,33
The present study has several limitations including the 
potential biases inherent to all observational studies. 
Additionally, our study did not reached the expected sample 
size, which might have underpowered the statistical analy-
ses conducted. Furthermore, Hb targets have been more 
recently reevaluated in several guidelines, thus these results 
may not reflect the current anemia treatment in CKD, but it 
alerts against a therapeutic inertia, making the results inter-
esting. Finally, in our study the main ESA prescribed was 
C.E.R.A, both in naïve and in patients that were shifted from 
another ESA. Although the Nephrology Units involved were 
selected solely for their interest in participating in the study, 
and not for the type of ESA prescribed, we cannot extrapolate 
that the rate of prescription of C.E.R.A in CKD patients not 
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